Strategic Alliances RayBiotech is actively expanding its ecosystem through partnerships with Allumiqs Corporation and Venebio Group, signaling a strong channel strategy and opportunities to co-sell integrated proteomics, multiomics workflows, and translational biomarker solutions.

Global Reach With presence in 85 countries and a broad proteomic discovery tool portfolio, there is a clear opportunity to target multinational life sciences customers seeking scalable, high-density antibody arrays and ELISA capabilities across research, preclinical, and clinical stages.

Prime Solutions The integration of proprietary antibody arrays with data analytics platforms via partners suggests a value proposition for customers needing end-to-end biomarker discovery, validation, and translational research support.

Mid-Market Focus Revenue range and employee size place RayBiotech in the mid-market segment, presenting sales opportunities with mid-size biotechs, contract research organizations, and translational centers seeking cost-effective, scalable proteomics tools.

Public Health Heritage Past collaborations delivering rapid antibody tests to NFL players and ongoing grant-backed funding indicate credibility in rapid deployment and research-grade diagnostics, appealing to healthtech, sports medicine, and academic institutions pursuing rapid biomarker workflows.